City of Hope | Strategic Alliance Partners

December 17, 2024

Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.

December 13, 2024

Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

December 10, 2024

Is it time to end the rhetoric that denies the benefit of antineoplastic pharmaceutical agents due to the absence of an OS improvement in a clinical trial?

December 08, 2024

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

December 02, 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

November 25, 2024

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

November 20, 2024

Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.

November 04, 2024

The program supports early-career researchers and helps build a cancer research workforce that better represents the diversity of America.

November 04, 2024

The oncology community must reconsider its approach to defining optimal dosing and scheduling of antineoplastic agents.

October 30, 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

October 28, 2024

Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.

October 25, 2024

Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.

October 24, 2024

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.

October 17, 2024

Idoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.

October 11, 2024

Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

October 11, 2024

Idoroenyi Amanam, MD, discusses potential treatment advancements in myelofibrosis and highlights the use of stem cell transplant in this disease.

October 02, 2024

Saro H. Armenian, DO, MPH, discusses ongoing research that aims to enhance the quality of care for childhood cancer survivors.

October 01, 2024

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

September 28, 2024

Saro H. Armenian, DO, MPH, raises awareness for childhood-related cancer interventions during Childhood Cancer Awareness Month.

September 26, 2024

Saro H. Armenian, DO, MPH, discusses treatment advancements that have helped reduce long-term adverse effects for patients in pediatric oncology.